SCHEMBL30639334

SCHEMBL30639334

OCC1(Nc2nc(Cl)nc3c2SCC3)CCC1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ LATS1 O95835 3/20 0.33
▸ LATS2 Q9NRM7 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14734141 1.00 LATS1 (0.33) LATS1LATS2
SCHEMBL373964 0.95 — —
SCHEMBL30678844 0.94 PDE4B (0.34) LATS1LATS2
SCHEMBL29277041 0.94 PDE4B (0.34) LATS1LATS2
SCHEMBL31622422 0.90 — —
SCHEMBL31630700 0.85 — —
SCHEMBL30758561 0.81 LATS1 (0.32) LATS1LATS2
SCHEMBL31670511 0.79 — —
SCHEMBL19560017 0.78 — —
SCHEMBL19624252 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678644-A1 SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Shanghai Yidi Biotechnology Co., Ltd. (CN) 2026-01-14 — — EP disclosed
EP-4674852-A1 PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE Innovstone Therapeutics Limited (CN) 2026-01-07 — — EP disclosed
US-20250270230-A1 NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL BOEHRINGER INGELHEIM INT (DE) 2025-08-28 — — US disclosed
WO-2025131986-A1 NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-06-26 — — WO disclosed
CN-120157682-A Deuterated heterocyclic compounds as PDE4B inhibitors and uses thereof 武汉人福创新药物研发中心有限公司 2025-06-17 — — CN disclosed
CN-119930644-A Phosphodiesterase 4B inhibitor and preparation method and application thereof 合肥医工医药股份有限公司 2025-05-06 — — CN disclosed
CN-119698422-A Aza condensed ring compound, preparation method and medical application thereof 苏州爱科百发生物医药技术有限公司 2025-03-25 — — CN disclosed
CN-118871444-A Preparation method and application of dihydro-thienopyrimidine derivative 上海翊石医药科技有限公司 2024-10-29 — — CN disclosed
WO-2024179493-A1 PREPARATION METHOD FOR AND USE OF DIHYDROTHIENOPYRIMIDINE DERIVATIVE 上海翊石医药科技有限公司 2024-09-06 — — WO disclosed
WO-2023241684-A1 PDE4B INHIBITOR 武汉人福创新药物研发中心有限公司 2023-12-21 — — WO disclosed
CN-117247395-A PDE4B inhibitors 武汉人福创新药物研发中心有限公司 2023-12-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270230-A1 NOVEL SYNTHETIC STEPS FOR THE MANUFACTURING METHOD OF THE PDE4B-INHIBITOR 1-({(5R)-2-[4-(5-CHLOROPYRIMIDINE-2-YL)PIPERIDINE-1-YL]-5-OXIDO-6,7-DIHYDROTHIENO[3,2-D]PYRIMIDINE-4-YL}AMINO)CYCLOBUTYL]METHANOL PDE4B, PDE3B, PDE5A LATS1 3710/4885LATS2 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback